Sogefi S.p.A. (GEF)

Overview

Theralase Technologies Inc. is a clinical stage pharmaceutical company deeply involved in the development of innovative treatments for various health issues, including cancers, bacterial and viral infections. With operations spanning Canada, the United States, and other international markets, the company leverages the potential of light activated photo dynamic compounds (PDCs) and their associated drug formulations. Beyond its pioneering work in pharmaceuticals, Theralase Technologies is also at the forefront of designing, developing, manufacturing, and marketing cutting-edge super-pulsed laser technology aimed at the healing of chronic knee pain, alongside a wider array of nerve, muscle, and joint conditions.

Products and Services

• TLD-1433

  Currently in Phase II clinical trials, TLD-1433 is Theralase Technologies’ forefront candidate for addressing the challenging treatment landscape of Bacillus Calmette Guérin - Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In-Situ. This innovative approach underlines the company's commitment to advancing cancer treatment options through research and development.

• TLC-2000

  Offering a superpulsed and visible red laser technology, the TLC-2000 stands out as a therapeutic device dedicated to accelerating the healing process by mitigating pain and inflammation. This product upholds safety by operating below the Maximal Permissible Exposure limit for tissue, making it a compelling option for health practitioners. It also includes related accessories for enhanced application and effectiveness.

• Controller-less Cool Laser Therapy Systems

  The TLC-900, TLC-300, and TLC-100 are key products within Theralase Technologies’ portfolio, directed at healthcare practitioners primarily for pain relief interventions. These systems epitomize the company's expertise in leveraging laser therapy to facilitate healing without the need for complex control mechanisms, thereby simplifying the therapeutic process.

• Research Collaborations

  In its quest to combat the global challenge posed by coronaviruses, Theralase Technologies has entered into research agreements with the University of Manitoba Medical Microbiology department and the National Microbiology Laboratory and Public Health Agency of Canada. These partnerships focus on the development of a coronavirus vaccine and the research and development of a Canadian-based SARS-CoV-2 vaccine, showcasing Theralase Technologies’ commitment to leveraging collective expertise for global health solutions.